Skip to main content

Mereo BioPharma Group plc

MREO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001719714

No open-market purchases or sales by Mereo BioPharma Group plc insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $18.0M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −3 vs. previous quarter
60
13F valueReported value at the end of Q2 2026
$18.0M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding MREO, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding MREO at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Mereo BioPharma Group plc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 16, 2024 (view filing)Sep 12-134 daysScots-Knight DeniseChief Executive OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−88.7K$4.30−$381.3K−9.9%808.9K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysLewicki John A.Chief Scientific OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−16.1K$4.30−$69.5K−17.0%78.6K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysSermon CharlesGeneral CounselSSaleAmerican Depositary Shares representing Ordinary Shares−30.9K$4.30−$133.0K−12.4%219.1K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysFox Christine AnnChief Financial OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−28.3K$4.30−$121.6K−24.1%89.3K after2 lots
Sep 16, 2024 (view filing)Sep 12-134 daysHughes-Wilson AlexandraSee RemarksSSaleAmerican Depositary Shares representing Ordinary Shares−148.1K$4.30−$637.0K−74.6%50.5K after4 lots
Aug 23, 2024 (view filing)Aug 221 dayPakianathan DeepikaDirectorSSaleAmerican Depositary Shares representing Ordinary Shares−105.2K$4.43−$466.2K−100.0%0 after
Jun 27, 2024 (view filing)Jun 25-262 daysSermon CharlesGeneral CounselSSaleAmerican Depositary Shares representing Ordinary Shares−46.4K$3.48−$161.5K−20.1%184.4K after2 lots
Jun 27, 2024 (view filing)Jun 25-262 daysLewicki John A.Chief Scientific OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−24.2K$3.48−$84.3K−33.2%48.8K after2 lots
Jun 27, 2024 (view filing)Jun 25-262 daysFox Christine AnnChief Financial OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−42.4K$3.48−$147.7K−42.4%57.6K after2 lots
Jun 27, 2024 (view filing)Jun 25-262 daysScots-Knight DeniseChief Executive OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−133.0K$3.48−$463.0K−15.8%709.5K after2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Mereo BioPharma Group plc at the end of Q2 2026; share changes are against Q1 2026.

See all 60 holders
Institutions holding MREO in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Rubric Capital Management LP15,307,347$4.86M0.04%00.0%Unchanged
683 Capital Management, LLC11,777,856$3.74M0.34%−222,144−1.9%Reduced
Bank of America Corp8,195,281$2.60M0.00%−60.0%Reduced
Defilade Capital Management, L.P.7,558,756$2.40M0.32%00.0%Unchanged
Newtyn Management, LLC3,000,000$953.1K0.12%−4,079,056−57.6%Reduced
Tejara Capital Ltd2,037,520$647.3K0.27%00.0%Unchanged
UBS Group AG1,447,627$460.3K0.00%−42,501−2.9%Reduced
Two Sigma Investments, LP1,319,241$419.1K0.00%+1,131,402+602.3%Added
EcoR1 Capital, LLC1,000,000$317.7K0.02%−12,368,855−92.5%Reduced
Jane Street Group, LLC774,944$246.2K0.00%+634,971+453.6%Added